Junshi Biosciences Surges Over 3% on Plans to Launch Pivotal Phase III Trials for Two Bispecific Antibody Drugs This Year

Stock News

Yesterday

JUNSHI BIO (01877) shares climbed more than 3% in Hong Kong trading, last up 3.07% at HK$17.11 with turnover reaching HK$19.955 million. The rally comes as investors reacted positively to the company's latest pipeline updates.

During the 2026 interim results briefing held on September 14, the company disclosed the most recent development progress of its core innovative drug pipeline. Management confirmed that both highly anticipated bispecific antibody candidates are scheduled to initiate pivotal Phase III clinical studies within 2026.

Among the two programs, JS203, a CD20/CD3-targeting bispecific antibody, is set to officially advance into the Phase III clinical stage. Meanwhile, JS207, which targets PD-1/VEGF, is currently in Phase II studies, with active exploration of combination therapies involving chemotherapy, monoclonal antibodies, and ADCs across multiple tumor types. This second candidate is also expected to commence Phase III trials within the same timeframe.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1121689900"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121689900\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121689900?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-14 14:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121689900","market":"other","top_or_hot":-1,"title":"Junshi Biosciences Surges Over 3% on Plans to Launch Pivotal Phase III Trials for Two Bispecific Antibody Drugs This Year","media":"Stock News","content":"<p><b>JUNSHI BIO</b> (01877) shares climbed more than 3% in Hong Kong trading, last up 3.07% at HK$17.11 with turnover reaching HK$19.955 million. The rally comes as investors reacted positively to the company's latest pipeline updates.<br><br>During the 2026 interim results briefing held on September 14, the company disclosed the most recent development progress of its core innovative drug pipeline. Management confirmed that both highly anticipated bispecific antibody candidates are scheduled to initiate pivotal Phase III clinical studies within 2026.<br><br>Among the two programs, JS203, a CD20/CD3-targeting bispecific antibody, is set to officially advance into the Phase III clinical stage. Meanwhile, JS207, which targets PD-1/VEGF, is currently in Phase II studies, with active exploration of combination therapies involving chemotherapy, monoclonal antibodies, and ADCs across multiple tumor types. This second candidate is also expected to commence Phase III trials within the same timeframe.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Junshi Biosciences Surges Over 3% on Plans to Launch Pivotal Phase III Trials for Two Bispecific Antibody Drugs This Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJunshi Biosciences Surges Over 3% on Plans to Launch Pivotal Phase III Trials for Two Bispecific Antibody Drugs This Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-14 14:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>JUNSHI BIO</b> (01877) shares climbed more than 3% in Hong Kong trading, last up 3.07% at HK$17.11 with turnover reaching HK$19.955 million. The rally comes as investors reacted positively to the company's latest pipeline updates.<br><br>During the 2026 interim results briefing held on September 14, the company disclosed the most recent development progress of its core innovative drug pipeline. Management confirmed that both highly anticipated bispecific antibody candidates are scheduled to initiate pivotal Phase III clinical studies within 2026.<br><br>Among the two programs, JS203, a CD20/CD3-targeting bispecific antibody, is set to officially advance into the Phase III clinical stage. Meanwhile, JS207, which targets PD-1/VEGF, is currently in Phase II studies, with active exploration of combination therapies involving chemotherapy, monoclonal antibodies, and ADCs across multiple tumor types. This second candidate is also expected to commence Phase III trials within the same timeframe.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01877","symbol_name":"君实生物","start_time":0,"source_url":"","article_id":"1121689900","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121689900","pubTimestamp":1789366938,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JUNSHI BIO (01877) shares climbed more than 3% in Hong Kong trading, last up 3.07% at HK$17.11 with turnover reaching HK$19.955 million. The rally comes as investors reacted positively to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01877":"君实生物","BK1583":"高瓴概念","VXUS":"国际股票ETF-Vanguard","KCAI":"KraneShares China Alpha Index ETF","BK4588":"碎股","BK1161":"生物科技","BK1515":"抗疫概念","BK4585":"ETF&股票定投概念"},"translate_title":"君实生物计划今年启动两款双特异性抗体药物关键III期试验，股价飙升逾3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"01877":1,"KCAI":1},"content_text":"JUNSHI BIO (01877) shares climbed more than 3% in Hong Kong trading, last up 3.07% at HK$17.11 with turnover reaching HK$19.955 million. The rally comes as investors reacted positively to the company's latest pipeline updates.During the 2026 interim results briefing held on September 14, the company disclosed the most recent development progress of its core innovative drug pipeline. Management confirmed that both highly anticipated bispecific antibody candidates are scheduled to initiate pivotal Phase III clinical studies within 2026.Among the two programs, JS203, a CD20/CD3-targeting bispecific antibody, is set to officially advance into the Phase III clinical stage. Meanwhile, JS207, which targets PD-1/VEGF, is currently in Phase II studies, with active exploration of combination therapies involving chemotherapy, monoclonal antibodies, and ADCs across multiple tumor types. This second candidate is also expected to commence Phase III trials within the same timeframe.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}